The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Eosinophil-neutrophil ratio as a sex-dependent prognostic marker in immune checkpoint therapy for metastatic NSCLC and transcriptomic evaluation of intratumoral eosinophil-T cell interaction.
 
Hyunwoo Kwon
No Relationships to Disclose
 
Mingjia Li
No Relationships to Disclose
 
Anjun Ma
No Relationships to Disclose
 
Cankun Wang
No Relationships to Disclose
 
Kenneth Chian
No Relationships to Disclose
 
Timothy Gauntner
No Relationships to Disclose
 
Nicholas Jones
No Relationships to Disclose
 
Adam Khorasanchi
No Relationships to Disclose
 
Daniel Spakowicz
No Relationships to Disclose
 
Kai He
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Obsidian Therapeutics; Perthera
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
Asrar Alahmadi
No Relationships to Disclose
 
Regan Michelle Memmott
Consulting or Advisory Role - Takeda
 
Jacob Kaufman
Consulting or Advisory Role - AstraZeneca
 
Peter G. Shields
No Relationships to Disclose
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; BMS Israel; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech; Genentech/Roche; GlaxoSmithKline; Intellisphere; InThought; Iovance Biotherapeutics; Janssen; Jazz Pharmaceuticals; JNJ; Johnson & Johnson/Janssen; Lilly; Merck; Merck KGaA; Mirati Therapeutics; MSD Oncology; NCCN/AstraZeneca; Novartis; Novocure; OncLive/MJH Life Sciences; Oncohost; Pfizer; PPD; Regeneron; Roche; Roche/Genentech; Sanofi
 
Gregory Alan Otterson
Consulting or Advisory Role - Novocure; OncLive/MJH Life Sciences
Research Funding - Apollomics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Revolution Medicines (Inst)
 
Carolyn J. Presley
Consulting or Advisory Role - Jazz Pharmaceuticals; Jazz Pharmaceuticals; Onc Live; Regeneron
 
Qin Ma
Employment - Daiichi Sankyo (I)
Consulting or Advisory Role - Merck
 
Zihai Li
Stock and Other Ownership Interests - Agenus (I); yuMed
Honoraria - Alphamab; Heat Biologics; Henlius
Consulting or Advisory Role - Abbvie; Alphamab; HANCHORBIO; Heat Biologics; Henlius; Ikonisys
Research Funding - Bristol-Myers Squibb; Heat Biologics
Patents, Royalties, Other Intellectual Property - Have a patent on HSP vaccine technology that was license to Agenus
 
Dwight Hall Owen
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Onc.AI (Inst); Palobiofarma (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Genentech